What Brainomix Announced About the REVISE PPF Quantitative CT Study

Brainomix said on 20 October 2026 that a multicentre study it calls REVISE PPF showed what it describes as the potential of quantitative CT for earlier detection of progressive pulmonary fibrosis. In the company account, the authors used measured CT readings to help identify radiological progression and progressive pulmonary fibrosis earlier than routine clinical assessment, with lead times of up to 28 months. The company says the CT measures were associated with a higher risk of future progressive pulmonary fibrosis and with higher mortality. It says the study was peer reviewed and published in the Annals of the American Thoracic Society, and that it included patients from three United States interstitial lung disease centres: the University of Alabama at Birmingham, Weill Cornell Medicine and the University of Chicago. The announcement names no patient numbers, no accuracy figures and no regulatory status.

Why the Brainomix REVISE PPF Results Matter to Imaging and Respiratory Leaders

A 28 month head start sounds dramatic, and the honest reading is narrower than the headline. Being associated with a higher risk of progression is a statistical finding, not a diagnosis, and the announcement gives no patient count and no accuracy numbers, so there is no way yet to tell how often the measure is right. Earlier detection also only pays off when there is something to do about it, and that case has to be made separately. What does matter is where this sits in a pattern: Brainomix already has its lung measurement carrying a main result in a Phase 3 drug trial, and a peer-reviewed study across three academic centres is the kind of outside evidence that argument needs. For an imaging or respiratory leader, the question to carry into a meeting is whether your own radiologists would change a follow-up plan on this measure, and what happens to clinic capacity if they do.

Where the Brainomix Update Comes From

Brainomix is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Brainomix original source.

How We Would Research the Brainomix REVISE PPF Study

The source gives us the starting point. This is how we would build the next layer of research around it.

  1. We would read the published paper in the Annals of the American Thoracic Society rather than the announcement about it, because the patient numbers and the accuracy figures are missing from the company summary.
  2. Then we would ask Brainomix how a lead time of up to 28 months was measured, and what the typical lead time was, since up to is the best case and not the normal case.
  3. We would ask the three named centres what they did differently once a scan was flagged, because an earlier warning changes nothing unless it changes a decision.